Pharma industry rejoices as German court slams down Unified Patent Court system

21 March 2020
germany_big

The German Constitutional Court has published its decision that the German Act implementing the Unified Patent Court system is unconstitutional.

After a long drawn out process and admittedly some flaws in this project, the German courts put a major halt on hopes of a unified patent or unified patent court (UPC). While, they did agree to re-evaluate the UPC after Brexit, it seems that the reality of a UP or UPC, has been buried for years to come. Says co-head of IP law firm Fieldfisher Benjamin Grizimek.

Germany was the final nail in the coffin, after many other countries had ratified the creation of a UPC. Germany understandably played leading role in the decision especially as within Europe, Germany is the largest filer of patents and the majority of patent litigation also takes place in the German courts, he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical